Tianjin Tianyao Pharmaceuticals (SHA:600488) secured registration approval for dexamethasone sodium phosphate active pharmaceutical ingredient (API) from Brazil's health surveillance agency.
Dexamethasone sodium phosphate is commonly used to treat allergies and autoimmune diseases, according to a Dec. 31 filing with the Shanghai bourse.
Shares of the company closed 1% lower Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.